Abstract
Background Identifying adverse drugs effects (ADEs) in children is essential for preventing disability and death from marketed drugs. At the same time, however, detection is challenging due to dynamic biological processes during growth and maturation, called ontogeny, that alter pharmacokinetics and pharmacodynamics. As a result, current data mining methodologies have been limited to event surveillance and have not focused on investigating adverse event mechanisms. There is an opportunity to design data mining methodologies to identify and evaluate drug event patterns within observational databases for ontogenic-mediated adverse event mechanisms. The first step of which is to establish statistical models that can identify temporal trends of adverse effects across childhood.
Results Using simulation, we evaluated a population stratification method (the proportional reporting ratio or PRR) and a population modeling method (the generalized additive model or GAM) to identify and quantify ADE risk at varying reporting rates and dynamics. We found that GAMs showed improved performance over the PRR in detecting dynamic drug event reporting across child developmental stages. Moreover, GAMs exhibited normally distributed and robust ADE risk estimation at all development stages by sharing information across child development stages.
Conclusions Our study underscores the opportunity for using population modeling techniques, which leverages drug event reporting across development stages, to identify adverse drug effect risk resulting from ontogenic mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors wish to acknowledge funding support from the National Institutes of General Medical Sciences (R35 GM1319050). N.P.G. and N.P.T. are both funded by R35 GM131905.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval was needed. All data was publically available.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets and code supporting the conclusions of this article are available in the evaluating_ontogenic_ade_risk Github repository, DOI: 10.5281/zenodo.4585585.
List of Abbreviations
- ADE
- adverse drug event
- FAERS
- Food and Drug Administration Adverse Event Reporting System
- GAM
- generalized additive model
- PRR
- proportional reporting ratio
- NICHD
- national institute of child and human development
- AUROC
- area under the receiver operating characteristic curve
- TPR
- true positive rate
- ATC
- anatomical therapeutic class
- DOI
- digital object identifier
